Not all leaders are good leaders.Perhaps you’ve lost an important executive or you’re establishing a local leadership team. You know that the leader you choose will have a major impact on the organization. So how can you avoid hiring the…
HOME > COLUMN
COLUMN
-
Maurer's Healthcare Insight (79) Back from the Saddle P. Reed Maurer
September 25, 2006
-
Maurer's Healthcare Insight (78) Infinite Value of a Good Boss P. Reed Maurer
August 28, 2006
-
Maurer's Healthcare Insight (77)
July 24, 2006
-
Maurer's Healthcare Insight (76)
June 26, 2006
-
Maurer's Healthcare Insight (75)
May 29, 2006
-
Maurer's Healthcare Insight (74)
April 10, 2006
-
Maurer's Healthcare Insight (73)
March 13, 2006
-
Maurer's Healthcare Insight (71)
December 19, 2005
-
Maurer's Healthcare Insight (70)
November 28, 2005
-
Maurer's Healthcare Insight(69)
November 14, 2005
-
Maurer's Healthcare Insight (68)
October 17, 2005
-
Maurer's Healthcare Insight (67)
September 26, 2005
-
Maurer's Healthcare Insight (66)
August 8, 2005
-
Maurer's Healthcare Insight (65)
July 11, 2005
-
Maurer's Healthcare Insight (64)
June 13, 2005
-
Maurer's Healthcare Insight (63)
May 30, 2005
-
Maurer's Healthcare Insight (62)
April 25, 2005
-
Maurer's Healthcare Insight (61)
March 28, 2005
-
Maurer's Healthcare Insight (60)
March 14, 2005
-
Maurer's Healthcare Insight (59)
December 6, 2004
ページ
Earlier this month, Health Minister Keizo Takemi called on the top executives of 13 major generic makers to restructure the industry with a product consolidation target of “around five companies per API.” While a variety of restructuring options are conceivable,…
The Japanese health ministry on December 22 approved a batch of medicines for additional indications, including Otsuka Pharmaceutical’s atypical antipsychotic Rexulti (brexpiprazole) and Zenyaku Kogyo’s anti-CD20 antibody Rituxan (rituximab).Rexulti is now newly indicated for the treatment of depression and depressive…
Authorized generic (AG) strategies taken by innovative drug makers might help soften the impact of generic competition in their businesses but such tactics might also accelerate the application of “G1”/“G2” price cuts for their off-patent brand-name medicines, a Jiho tally…
Japan’s health ministry announced new NHI prices to be applied in April under the FY2022 drug price revision in the official gazette on March 4, with the earlier application of so-called “G1” price cuts to be implemented for the first…